Actinium Pharmaceuticals, Inc.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $90.0K
- Net income
- -$33.9M
- Total assets
- $51.8M
- Market cap
- $33.9M
- Operating margin
- -40274.4%
- Net margin
- -37652.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $90.0K
- Operating expenses
- $36.3M
- Operating income
- -$36.2M
- Net income
- -$33.9M
- EPS (basic)
- $-1.09
- EPS (diluted)
- $-1.09
Balance sheet
- Total assets
- $51.8M
- Current assets
- $49.4M
- Total liabilities
- $43.9M
- Current liabilities
- $8.0M
- Shareholders’ equity
- $7.8M
Cash flow
- Operating cash flow
- -$24.6M
- Investing cash flow
- -$104.0K
- Financing cash flow
- -$217.0K
- Net cash flow
- -$24.9M
Statements via Polygon.io (SEC filings)
- Market cap
- $33.9M
- EPS (diluted)
- $-1.09
- Shares outstanding
- 32.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 19, 2007
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $33.9M in FY2025.
- Revenue declined 92% from FY2021 to FY2025.
- Trading 45% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Actinium Pharmaceuticals, Inc..
Write a review
News about Actinium Pharmaceuticals, Inc.
News & sentiment via Polygon.io
